WO2019216567A1 - 상아질 지각과민증 완화를 위한 구강 청결용 조성물 - Google Patents
상아질 지각과민증 완화를 위한 구강 청결용 조성물 Download PDFInfo
- Publication number
- WO2019216567A1 WO2019216567A1 PCT/KR2019/004635 KR2019004635W WO2019216567A1 WO 2019216567 A1 WO2019216567 A1 WO 2019216567A1 KR 2019004635 W KR2019004635 W KR 2019004635W WO 2019216567 A1 WO2019216567 A1 WO 2019216567A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dentin
- peptide
- composition
- weight
- amino acid
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Definitions
- the present invention relates to a composition for oral cavity cleaning, and more particularly, to an oral cleaning composition for preventing or alleviating hypersensitivity by inducing physiological remineralization of dentin defects constituting teeth.
- Dentinic hypersensitivity commonly referred to as 'single'
- 'single' Dentinic hypersensitivity
- 'single' is a common symptom experienced by 8% to 57% of the adult population.
- 72.5% to 98% of patients suffer from sickness (Source: National Health Information Portal Medical Information; http://health.cdc.go.kr/health /Main.do).
- Dentinic hypersensitivity can be defined as pain caused by the dentinal tubules passing all external stimuli to the nerves in the pulp as they are, making them more sensitive to the same stimulus than usual. There is no nerve in the dentin itself, but we feel that it is cold because cold stimuli are transmitted through the dentin tubule to the nerves inside the pulp.
- dentin tubules that run from pulp to enamel.
- the inside of the tube is filled with liquid and has a larger diameter and dense structure toward the pulp, which allows the external stimulus to be quickly transmitted to the inner pulp nerve. If the dentin in contact with the outside is damaged and the area of the dentinal tubule is in contact with the outside, it may be more sensitive than usual to the same stimulus.
- potassium phosphate salt (K 2 HPO 4 ) is widely used as a method for interfering with pain transmission of nerve signaling.
- potassium phosphate salts are not only effective in reducing pain, but also have to be used repeatedly and repeatedly.
- the method of occlusive tubular blockade uses a heterogeneous substance different from the dentin, so that a gap is formed in the peripheral boundary area or the nerve is exposed again from the blockage part, and the syringy symptoms recur.
- mouthwashes for relieving dentin hypersensitivity (syringe) are mostly fluorine-containing products.
- Fluoride coats teeth and binds the exposed dentinal tubules due to strong binding to calcium components present in saliva. It is known to have a relaxing effect. However, fluoride is known to have side effects that can cause damage to the human immune system, arthritis, back pain, osteoporosis, etc. after long-term use.
- An object of the present invention is to provide a composition for oral cleaning comprising a peptide (peptide) to prevent or alleviate perceptual hypersensitivity by closing the defect of the dentin tube exposed by physiological remineralization of the dentin.
- Oral cleansing composition for alleviating dentin hypersensitivity for solving the above technical problem provides a composition for oral cleansing for alleviating dentin hypersensitivity including a peptide consisting of the amino acid sequence of the general formula 1 do.
- R 1 is arginine (R), lysine (K) or glutamine (Q);
- R2 is arginine (R) or glutamine (Q);
- R3, R4 and R5 are arginine (R) or lysine (K), respectively;
- R6 is asparagine (N) or serine (S);
- R7 and R8 are lysine (K) or tyrosine (Y).
- the peptide may be composed of any one amino acid sequence of SEQ ID NO: 1 to 96.
- 0.00005-0.00015 parts by weight of the peptide may be included based on 100 parts by weight of the composition.
- cetylpyridinium chloride may be included based on 100 parts by weight of the composition.
- the composition for oral cleansing may include 85-87 parts by weight of purified water, 1.7-2.9 parts by weight of surfactant, and 0.0045-0.0055 parts by weight of citric acid hydrate based on 100 parts by weight of the composition.
- the surfactant may be poloxamer and / or polysorbate20.
- the surfactant may comprise 12-14% by weight of the poloxamer407, 86-88% by weight of polysorbate20.
- the composition for oral cleansing may include 9-11 parts by weight of a humectant based on 100 parts by weight of the composition.
- the humectant may be D-sorbitol solution and / or concentrated glycerin.
- the humectant may include 45-55 wt% of the D-sorbitol solution and 45-55 wt% of the concentrated glycerin.
- the present invention can provide a composition for oral cleansing comprising a peptide that prevents or alleviates perceptual hypersensitivity by closing the defect of the dentin tube exposed by physiological remineralization of dentin.
- Figure 1a is a graph showing the results of comparing the effect of the peptides contained in the composition for oral cleansing for relieving dentin hypersensitivity according to an embodiment of the present invention on DSPP expression, an odontoblast differentiation marker gene.
- Figure 1b is a graph showing the result of comparing the expression level of the DSPP gene, which is an odontoblast differentiation marker in the MDPC-23 cells treated with the peptide contained in the composition for oral clearance for relieving dentin hypersensitivity according to an embodiment of the present invention. .
- Figure 1c shows the dendritic marker markers of DSPP, Dmp1 and Nestin genes in MDPC-23 cells treated with the peptides of Groups 11 and 12 contained in the composition for oral cleansing for alleviating dentin hypersensitivity according to an embodiment of the present invention
- a graph showing the results of comparing expression levels.
- Figure 1d is a graph showing the results of the evaluation of cytotoxicity to the pulp tissue cells of the peptides contained in the composition for oral cleansing for alleviating dentin hypersensitivity according to an embodiment of the present invention.
- Figure 2 shows the dentinal tubular permeability of the oral cleansing composition for relieving dentin hypersensitivity according to an embodiment of the present invention, after mixing the fluorescent dye reagent (Rhodamine B) for 1 minute to the exposed dentinal tubules The results observed with a fluorescence microscope are shown.
- Figure 3 shows the results of comparing the dentin capillary blockage ability of the composition for oral cleansing for alleviating dentin hypersensitivity in accordance with Comparative Example 3-1 and Comparative Example 3-2 and the embodiment of the present invention.
- AC shows dentin dentin tubules treated with purified water only (Comparative Example 3-1), and DF is free of peptides in the composition of the composition for oral cleansing for alleviating dentin hypersensitivity according to an embodiment of the present invention.
- GI is showing the dentinal tubules reacted with the composition for oral cleaning for relieving dentin hypersensitivity according to an embodiment of the present invention (Size bars: A, D, G, 100 ⁇ m; B, E, H, 20 ⁇ m; C, F, I, 10 ⁇ m).
- the dentin tube exposed to the dentin tube was allowed to react for 1 day, once, and 1 minute, and then stored in artificial saliva. After repeating this procedure for 2 weeks, the capillary blockade was observed by scanning electron microscopy.
- Figure 4 is an enlarged portion of the dentin capillary blocked by the oral cleansing composition for relieving dentin hypersensitivity in accordance with an embodiment of the present invention, shows the result of remineralization in the blocked dentin capillary and dentin surface.
- an odontoblast may refer to a cell that synthesizes and secretes proteins and polysaccharides constituting the substrate of the dentin in a cell.
- a columnar cell that forms a layer of cell layer at the periphery of the pulp in contact with the dentin (the calcified dentin), and faces the enamel group of the cells of the dermal papilla (becomes a cell derived from the mesodermal mesenchyme).
- Peptides included in the composition for oral cleansing for alleviating dentin hypersensitivity according to an embodiment of the present invention do not exhibit cytotoxicity, but are the odontoblast differentiation marker genes DSPP, Dmp1 and Nestin.
- the expression level of the gene may be increased, and when implanted in vivo with the pulp tissue cells, the pulp tissue cells may be characterized by forming dentin / dimension-like tissue.
- the odontoblast differentiation peptide also includes a variant peptide having an amino acid sequence which differs from one or more amino acid residues as long as it can exhibit dentin regeneration or therapeutic effect of dentin hypersensitivity.
- amino acid exchanges in proteins and polypeptides that do not alter the activity of the molecule as a whole are known in the art.
- the most commonly occurring exchanges are amino acid residues Ala / Ser, Val / Ile, Asp / Glu, Thr / Ser, Ala / Gly, Ala / Thr, Ser / Asn, Ala / Val, Ser / Gly, Thy / Phe, Ala / Exchange between Pro, Lys / Arg, Asp / Asn, Leu / Ile, Leu / Val, Ala / Glu, Asp / Gly.
- the peptide may include a peptide having an increased structural stability against heat, pH, or the like, or an increased regeneration-promoting ability of dentin or pulp tissue due to variation or modification of the amino acid sequence.
- glutamine an acidic amino acid located at No. 3 of the peptide of SEQ ID NO: 1 provided in the present invention
- glutamine an acidic amino acid located at No. 3 of the peptide of SEQ ID NO: 1 provided in the present invention
- glutamine an acidic amino acid located at No. 3 of the peptide of SEQ ID NO: 1 provided in the present invention
- Arginine a basic amino acid located at positions 4 or 5 of the peptide of SEQ ID NO: 1 may exhibit the effect of the peptide provided in the present invention even when substituted with an acidic amino acid glutamine or a basic amino acid lysine
- Lysine a basic amino acid located at Nos.
- the acidic amino acid, basic amino acid, or aromatic amino acid constituting the oocyte differentiation-promoting peptide may have the same effect even when substituted with another acidic amino acid, basic amino acid, neutral amino acid, or aromatic amino acid, thereby constituting the oocyte differentiation promoting peptide. It is apparent that variant peptides having a sequence in which the amino acid sequence differs from one or more amino acid residues are also included in the category of the odontoblast differentiation peptide.
- the peptides provided in the present invention can exhibit the effects of the peptide provided in the present invention.
- the peptide may have a form in which 1 to 300 amino acids are added to the N-terminus or C-terminus of the peptide, and as another example, 1 to 100 amino acids may be added to the N-terminus or C-terminus of the peptide. It may be in an added form, and as another example, may be a form in which 1 to 24 amino acids are added to the N-terminus or C-terminus of the peptide.
- the odontoblast differentiation peptide which has an effect of increasing the mRNA level of the DSPP gene, is known as It has been shown to have an effect of promoting dentin regeneration (Taduru Sreenath et al., THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 278, No. 27, Issue of July 4, pp. 24874-24880, 2003; William T. Butler et al, Connective Tissue Research, 44 (Suppl. 1): 171-178, 2003).
- Peptides included in the composition for oral cleansing for alleviating dentin hypersensitivity may be used in the form of a peptide alone, the peptide may be used in the form of a polypeptide that is repeatedly connected two or more times, It may also be used in the form of a complex in which a drug that exhibits the effect of differentiating or dentin regenerating the oblasts at the N- or C-terminus of the peptide.
- Peptides (SEQ ID NO: 1) were synthesized by 9-fluorenylmethyloxycarbonyl (Fmoc) method, and the amino acids of the synthesized peptides were substituted to synthesize peptides of each group (Tables 1 to 12).
- the peptide of group 1 was synthesized by substituting lysine or arginine for amino acids 5 to 7 of the peptide of SEQ ID NO: 1 or the peptide of SEQ ID NO: 1 (Table 1).
- the peptide of group 2 was synthesized by substituting lysine or arginine for amino acids 5 to 7 of the peptide of SEQ ID NO: 1 and replacing amino acid 8 with serine (Table 2).
- the peptide of Group 3 was synthesized by substituting amino acids 5 to 7 of the peptide of SEQ ID NO: 1 with lysine or arginine and substituting amino acid 9 with tyrosine (Table 3).
- the peptides of Group 4 replace amino acids 5 to 7 of the peptide of SEQ ID NO: 1 with lysine or arginine, amino acid 8 with serine, amino acid 9 with tyrosine, and amino acid 10 with Synthesis by substitution with lysine (Table 4).
- the peptide of group 5 was synthesized by replacing amino acid 3 of the peptide of SEQ ID NO: 1 with arginine, amino acid 4 with glutamine, and amino acids 5 through 7 with lysine or arginine (Table 5 ).
- the peptide of group 6 replaces amino acid 3 of the peptide of SEQ ID NO: 1 with arginine, amino acid 4 with glutamine, amino acids 5 through 7 with lysine or arginine, and amino acid 8 with Synthesis by substitution with serine (Table 6).
- the peptides of group 7 replace amino acid 3 of the peptide of SEQ ID NO: 1 with arginine, amino acid 4 with glutamine, amino acids 5-7 with lysine or arginine, amino acid 9 Substituted with tyrosine and synthesized by replacing amino acid 10 with lysine (Table 7).
- the peptide of group 8 replaces amino acid 3 of the peptide of SEQ ID NO: 1 with arginine, amino acid 4 with glutamine, amino acids 5 through 7 with lysine or arginine, and amino acid 8 with Substituted with serine, amino acid 9 was replaced with tyrosine and amino acid 10 was replaced with lysine (Table 8).
- the peptide of group 9 was synthesized by replacing amino acid 3 of the peptide of SEQ ID NO: 1 with lysine, amino acid 4 with glutamine, and amino acids 5-7 with lysine or arginine (Table 9 ).
- the peptide of group 10 substitutes lysine for amino acid 3 of the peptide of SEQ ID NO: 1, replaces amino acid 4 with glutamine, replaces amino acids 5-7 with lysine or arginine, and amino acid 8 Synthesis by substitution with serine (Table 10).
- Peptides of group 10 SEQ ID NO: Amino acid sequence (N-C) 7374757677787980 KYKQRKKSKYKYKQRKRSKYKYKQRRKSKYKYKQRRRSKYKYKQKKKSKYKYKQKRKSKYKYKQKKRSKYKYKQKRRSKY
- the peptide of group 11 substitutes lysine for amino acid 3 of the peptide of SEQ ID NO: 1, replaces amino acid 4 with glutamine, replaces amino acids 5-7 with lysine or arginine, and amino acid 9 Substituted with tyrosine and synthesized by replacing amino acid 10 with lysine (Table 11).
- the peptides of group 12 replace amino acid 3 of the peptide of SEQ ID NO: 1 with lysine, amino acid 4 with glutamine, amino acids 5-7 with lysine or arginine, amino acid 8 Substituted with serine, amino acid 9 was replaced with tyrosine and amino acid 10 was replaced with lysine (Table 12).
- Example 2 Verification of the Promoting Effect of Dentin Using Dentin Cells
- Example 2-1 Verification of Peptide Effects on Dentin Sialophosphoprotein (DSPP) Promoter Activity
- mouse-derived dendritic cells MDPC-23 cells, contained 10% FBS.
- DMEM medium incubated at 5% CO 2 and 37 °C conditions.
- the cultured MDPC-23 cells were dispensed in a 24-well plate at 5 X 10 4 cells per well, incubated for 24 hours, and then cultured into the cultured cells using lipofectamine Plus TM reagent, pGL3.
- the vector was transformed by introducing a recombinant vector into which the DSPP promoter and luciferase gene were introduced.
- the transformed MDPC-23 cells were treated with the peptides of Groups 1 to 12 synthesized in Example 1 and incubated for 48 hours, and then luciferase activity was measured in each of the transformed MDPC-23 cells. , And compared the average level calculated for each group (Fig. 1a). At this time, the transformed MDPC-23 cells not treated with the odontoblast differentiation peptide were used as a control.
- Figure 1a is a graph showing the results of comparing the effect of each peptide provided by the present invention on DSPP expression, an odontoblast differentiation marker gene for each group.
- each peptide provided in the present invention showed a value of about 1.3 times or more of the luciferase activity level measured in the control group as a whole, but shows a difference for each group, the peptide of the group 12 has the highest Peptides that exhibited levels of luciferase activity and the next highest levels of luciferase activity were identified as group 11 peptides.
- the peptide provided in the present invention was found to exhibit the effect of activating the DSPP promoter.
- the MDPC-23 cells cultured in Example 2-1 were treated with the peptides of each group synthesized in Example 1, incubated for 48 hours, and then were the oblast differentiation marker genes expressed in the MDPC-23 cells.
- MRNA levels of DSPP genes were measured, and the mRNA levels of each of the DSPP genes measured above were converted in relative proportion to the mRNA levels of DSPP genes measured in the control group (Tables 13-24).
- the average value of the mRNA level of the DSPP gene measured according to the peptide of each group was compared for each group (Fig. 1b). In this case, MDPC-23 cells not treated with the odontoblast differentiation peptide were used as controls.
- the synthesized cDNA was used for real time polymerase chain reaction.
- Real-time polymerase chain reaction was performed in ABI PRISM 7500 sequence detection system (Applied Biosystems) using each primer below and SYBR GREEN PCR Master Mix (Takara, Japan).
- Dspp_F 5'-ATTCCGGTTCCCCAGTTAGTA-3 '(SEQ ID NO: 97)
- Gapdh_F 5'-AGGTCGGTGTGAACGGATTTG-3 '(SEQ ID NO: 99)
- Gapdh_R 5'-TGTAGACCATGTAGTTGAGGTCA-3 '(SEQ ID NO: 100)
- Figure 1b is a graph showing the result of comparing the expression level of the DSPP gene, which is an oblast differentiation marker in MDPC-23 cells treated with the oocyte differentiation promoting peptide.
- the treatment of the oocyte differentiation-promoting peptide increases the mRNA level of the DSPP gene, an odontoblast differentiation marker, and similar to that of Figure 1a, a value of about 1.3 times greater than the DSPP gene mRNA level measured in the control group. It was confirmed that it represents.
- Example 2-3 Verification of the Effect of Peptides on the Expression Levels of DSPP, Dmp1, and Nestin Genes, the Tumor Differentiation Marker Gene
- the odontoblast differentiation peptide can increase the mRNA level of the DSPP gene, and in particular, the peptides of groups 11 and 12 can increase the mRNA level of the DSPP gene by at least three times or more. It was confirmed.
- each of the following primers was used, except that the peptides of groups 11 and 12 were used as peptides, followed by the same method as in Example 2-2, and the dendritic cells on the expression level of Dmp1 and Nestin gene The effect of the differentiation-promoting peptides was measured and the average level calculated for each group was compared (FIG. At this time, MDPC-23 cells not treated with the odontoblast differentiation peptide were used as a control group, and mRNA level of DSPP gene was used as a comparison group.
- Dmp1_F 5'-CATTCTCCTTGTGTTCCTTTGGG-3 '(SEQ ID NO: 101)
- Dmp1_R 5'-TGTGGTCACTATTTGCCTGTG-3 '(SEQ ID NO: 102)
- Figure 1c is a graph showing the results of comparing the expression level of the DSPP, Dmp1 and Nestin genes of the odontoblast differentiation marker genes in MDPC-23 cells treated with peptides of groups 11 and 12.
- the treatment of the oocyte differentiation-promoting peptide increased the expression levels of the DSPP, Dmp1 and Nestin genes, which are the oocyte differentiation marker genes, but showed a difference in the level of increase for each gene, rather than the peptide of group 11 It was found that the peptides of group 12 increased to higher levels.
- the differentiation marker genes are known as genes involved in the process of odontoblast differentiation and dentin calcification, the peptide provided in the present invention was analyzed to have an effect of promoting dentin regeneration.
- Example 2-4 Cytotoxicity Evaluation of Peptides for Promoting Regeneration of Dentin or Pulp Tissue and Dentin Hypersensitivity to Pulp Cells
- pulp tissue cells were divided into 96 well plates so as to have a number of about 3 ⁇ 10 3 cells per well, incubated for 24 hours, and then treated with a group 11 or 12 peptide at a concentration of 10 or 50 ⁇ g / ml. And again incubated for 1, 3 or 5 days. After the incubation was terminated, the cultured cells were washed with PBS, 20 ⁇ l of MTT solution was added, and then reacted at about 37 ° C. for 4 hours. After the reaction was completed, the MTT solution was removed, 100 ⁇ l of DMSO was added, and the absorbance was measured at a wavelength of 540 nm (FIG. 1D). In this case, pulp tissue cells cultured without the peptide were used as a control.
- Figure 1d is a graph showing the results of evaluating the cytotoxicity of the odontoblast differentiation peptide against pulp tissue cells. As shown in Figure 1d, it was confirmed that the survival rate of the pulp tissue cells showed the same level as the control group even when the odontoblast differentiation promoting peptide was added.
- Poloxamer 407 was added to purified water and stirred for about 30 minutes in a stirrer (stirring conditions: PADDLE 15-20 rpm, DISPERSE 400-500 rpm)
- Polysorbate 20 (Tween 20), golden extract, green tea extract, chamomile extract, rosemary extract and mint flavor (HF-3585) are added to the mixture and stirred for about 30 minutes in a stirrer (stirring condition: PADDLE 15-20 rpm, DISPERSE) 400 ⁇ 500 rpm)
- the oocyte differentiation promoting peptide (SEQ ID NO: 96) is mixed to about 0.0001%, and then citric acid hydrate (citric acid hydrate) is added to adjust the pH to 5.5-6.0.
- Composition table of oral cleansing compositions for alleviating dentin hypersensitivity according to Example 3 of the present invention division Raw material name Weight (Wt%) One solvent Purified water 86.25 Surfactants Poloxamer 407 0.3 Peptide Odontoblast Differentiation Peptides 0.0001 2 Preservative Potassium Sorbate 0.1 chief ingredient Cetylpyridinium Chloride 0.055 Sweetener Xylitol One Acesulfame Potassium 0.05 pH regulator Citric Acid Hydrate (Citrate Hydrate) 0.005 coloring agent Blue 1 0.00025 Humectant D-sorbitol solution 5 Concentrated glycerin 5 3 Surfactants Polysorbate 20 2 (Tween 20) Flavor Golden extract 0.01 Green Tea Extract (Organic) 0.01 Chamomile Extract (Organic) 0.01 Rosemary Extract (Organic) 0.01 Mint flavor HF-6585 0.2 Sum 100
- Example 3 The components of Example 3 were prepared so that all components other than the purified water were not included in the odontoblast differentiation promoting peptide (SEQ ID NO: 96).
- the crown of the extracted tooth is cut horizontally with a diamond saw to expose the ivory tubules and then washed twice with phosphate buffer for about 5 minutes.
- the previously cut tooth was reacted with 0.5 M ethylenediaminetetraacetic acid (EDTA, pH 7.4) solution for about 5 minutes and washed twice with phosphate buffer for 5 minutes.
- EDTA ethylenediaminetetraacetic acid
- Oral cleansing composition containing an odontoblast differentiation peptide (SEQ ID NO: 96) is added to the oral cleansing composition to alleviate the hypersensitivity of the dentin, so that 0.1% of fluorescent dye is included and mixed well.
- the reacted cleaved teeth were washed twice in phosphate buffer for about 5 minutes, and then cut into a length of about 0.5 mm vertically so that the dentinal tubules of the cleaved teeth appeared long using a diamond saw (Fig. 2). Reference).
- composition of the artificial saliva is shown in Table 26 below.
- potassium phosphate (K 2 HPO 4 ) was added last.
- ⁇ pH of artificial saliva is measured in the vicinity of 7.2, similar to human saliva.
- a tooth of an extracted person was cut transversely using a diamond saw to fabricate a dentin specimen with 1 mm thick dentinal tubule exposed.
- the dentin specimens were reacted with about 32% phosphoric acid solution for about 5 minutes to completely expose the dentin tubules and washed three times with purified water for 5 minutes. Then, the dentin specimens were washed six times in an ultrasonic cleaner for about five minutes to fully expose the dentin tubules.
- composition for oral cleansing for alleviating dentin hypersensitivity according to Example 3, reacted with the dentinal tubule specimens for about 1 minute and then reacted with artificial saliva for about 24 hours.
- composition for oral cleansing prepared in Comparative Example 3-2 reacted with ivory tubule specimens for about 1 minute and then reacted with artificial saliva for about 24 hours.
- FIG. 3 shows the result of comparing the dentin capillary blockage ability of the composition for oral cleansing for alleviating dentin hypersensitivity in accordance with Comparative Example 3-1 and Comparative Example 3-2 and the embodiment of the present invention, more specifically , AC shows dentin dentin tubules treated only with purified water (Comparative Example 3-1), DF is a peptide of the oral cleansing composition for relieving dentin hypersensitivity according to an embodiment of the present invention It shows the dentinal tubules reacted with the contained oral cleaning composition (Comparative Example 3-2), GI shows the dentinal tubules reacted with the oral cleaning composition for relieving dentin hypersensitivity according to an embodiment of the present invention (Size bars: A, D, G, 100 ⁇ m; B, E, H, 20 ⁇ m; C, F, I, 10 ⁇ m).
- Figure 4 is an enlarged portion of the dentin capillary blocked by the oral cleansing composition for relieving dentin hypersensitivity in accordance with an embodiment of the present invention, shows the result of remineralization in the blocked dentin capillary and dentin surface.
- Oral cleansing composition for relieving perceptual hypersensitivity forms a thin film in the dentin and strongly binds to the exposed dentin tube and dentin surface by binding strongly to the phosphate-calcium ions present in the dentin tube and saliva Induces anger to effectively block ivory tubules.
- composition for oral cleansing for alleviating dentin hypersensitivity is effective in relieving and / or preventing symptomatic symptoms by inducing remineralization not only on the exposed dentinal tubule but also in the dentinal tubule. Can be represented.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
서열번호 | 아미노산 서열(N-C) |
12345678 | KYQRRKKNKYKYQRRKRNKYKYQRRRKNKYKYQRRRRNKYKYQRKKKNKYKYQRKRKNKYKYQRKKRNKYKYQRKRRNKY |
서열번호 | 아미노산 서열(N-C) |
910111213141516 | KYQRRKKSKYKYQRRKRSKYKYQRRRKSKYKYQRRRRSKYKYQRKKKSKYKYQRKRKSKYKYQRKKRSKYKYQRKRRSKY |
서열번호 | 아미노산 서열(N-C) |
1718192021222324 | KYQRRKKNYKKYQRRKRNYKKYQRRRKNYKKYQRRRRNYKKYQRKKKNYKKYQRKRKNYKKYQRKKRNYKKYQRKRRNYK |
서열번호 | 아미노산 서열(N-C) |
2526272829303132 | KYQRRKKSYKKYQRRKRSYKKYQRRRKSYKKYQRRRRSYKKYQRKKKSYKKYQRKRKSYKKYQRKKRSYKKYQRKRRSYK |
서열번호 | 아미노산 서열(N-C) |
3334353637383940 | KYRQRKKNKYKYRQRKRNKYKYRQRRKNKYKYRQRRRNKYKYRQKKKNKYKYRQKRKNKYKYRQKKRNKYKYRQKRRNKY |
서열번호 | 아미노산 서열(N-C) |
4142434445464748 | KYRQRKKSKYKYRQRKRSKYKYRQRRKSKYKYRQRRRSKYKYRQKKKSKYKYRQKRKSKYKYRQKKRSKYKYRQKRRSKY |
서열번호 | 아미노산 서열(N-C) |
4950515253545556 | KYRQRKKNYKKYRQRKRNYKKYRQRRKNYKKYRQRRRNYKKYRQKKKNYKKYRQKRKNYKKYRQKKRNYKKYRQKRRNYK |
서열번호 | 아미노산 서열(N-C) |
5758596061626364 | KYRQRKKSYKKYRQRKRSYKKYRQRRKSYKKYRQRRRSYKKYRQKKKSYKKYRQKRKSYKKYRQKKRSYKKYRQKRRSYK |
서열번호 | 아미노산 서열(N-C) |
6566676869707172 | KYKQRKKNKYKYKQRKRNKYKYKQRRKNKYKYKQRRRNKYKYKQKKKNKYKYKQKRKNKYKYKQKKRNKYKYKQKRRNKY |
서열번호 | 아미노산 서열(N-C) |
7374757677787980 | KYKQRKKSKYKYKQRKRSKYKYKQRRKSKYKYKQRRRSKYKYKQKKKSKYKYKQKRKSKYKYKQKKRSKYKYKQKRRSKY |
서열번호 | 아미노산 서열(N-C) |
8182838485868788 | KYKQRKKNYKKYKQRKRNYKKYKQRRKNYKKYKQRRRNYKKYKQKKKNYKKYKQKRKNYKKYKQKKRNYKKYKQKRRNYK |
서열번호 | 아미노산 서열(N-C) |
8990919293949596 | KYKQRKKSYKKYKQRKRSYKKYKQRRKSYKKYKQRRRSYKKYKQKKKSYKKYKQKRKSYKKYKQKKRSYKKYKQKRRSYK |
서열번호 | DSPP 유전자의 mRNA 수준 | |
평균 | 표준편차 | |
12345678 | 1.7541.6461.4641.8551.6391.7461.8641.639 | 0.1320.0920.2210.1020.0570.0910.1320.032 |
서열번호 | DSPP 유전자의 mRNA 수준 | |
평균 | 표준편차 | |
910111213141516 | 1.8541.7461.6391.5481.6851.8461.9641.739 | 0.0320.0520.2010.0270.0770.1410.2790.092 |
서열번호 | DSPP 유전자의 mRNA 수준 | |
평균 | 표준편차 | |
1718192021222324 | 2.1172.3191.9312.5531.8932.4122.1712.212 | 0.2090.0920.1020.0990.1320.0720.2810.111 |
서열번호 | DSPP 유전자의 mRNA 수준 | |
평균 | 표준편차 | |
2526272829303132 | 2.3712.1931.9932.4531.8832.5122.3712.219 | 0.0890.0520.2020.1920.1010.2090.1390.302 |
서열번호 | DSPP 유전자의 mRNA 수준 | |
평균 | 표준편차 | |
3334353637383940 | 1.7121.9311.9832.3191.5972.1161.7122.219 | 0.0910.1720.1020.2920.3010.2110.1910.212 |
서열번호 | DSPP 유전자의 mRNA 수준 | |
평균 | 표준편차 | |
4142434445464748 | 1.5461.5861.6691.7931.5321.8871.6971.558 | 0.0910.1030.0950.2030.3100.0770.0090.201 |
서열번호 | DSPP 유전자의 mRNA 수준 | |
평균 | 표준편차 | |
4950515253545556 | 1.9231.8871.6012.0191.5921.4371.6631.701 | 0.1920.0070.0820.1350.2220.3410.0940.109 |
서열번호 | DSPP 유전자의 mRNA 수준 | |
평균 | 표준편차 | |
5758596061626364 | 2.0391.9981.7922.1072.3011.6721.7691.967 | 0.0820.1720.0070.2010.0190.3080.0850.039 |
서열번호 | DSPP 유전자의 mRNA 수준 | |
평균 | 표준편차 | |
6566676869707172 | 1.7231.6271.7771.4322.0111.9271.8792.011 | 0.0720.2910.0270.4100.0810.1050.0600.009 |
서열번호 | DSPP 유전자의 mRNA 수준 | |
평균 | 표준편차 | |
7374757677787980 | 2.0352.0111.9972.3511.7292.6352.2311.837 | 0.0210.0630.0590.1090.1110.0910.0770.201 |
서열번호 | DSPP 유전자의 mRNA 수준 | |
평균 | 표준편차 | |
8182838485868788 | 3.0923.3613.5723.7023.6703.7053.8884.021 | 0.1520.0980.2090.3010.0880.1370.0720.301 |
서열번호 | DSPP 유전자의 mRNA 수준 | |
평균 | 표준편차 | |
8990919293949596 | 4.2114.8114.3624.2114.5253.8364.6205.211 | 0.4130.3020.1820.2870.2500.0990.4010.371 |
구 분 | 원 료 명 | 중 량 (Wt%) | |
1 | 용제 | 정제수 | 86.25 |
계면활성제 | 폴록사머407 | 0.3 | |
펩타이드 | 상아모세포 분화촉진 펩타이드 | 0.0001 | |
2 | 보존제 | 소르빈산 칼륨 | 0.1 |
주성분 | 염화세틸피리디늄 | 0.055 | |
감미제 | 자일리톨 | 1 | |
아세설팜칼륨 | 0.05 | ||
pH조절제 | 시트르산수화물 (구연산수화물) | 0.005 | |
착색제 | 청색 1호 | 0.00025 | |
습윤제 | D-소르비톨액 | 5 | |
농글리세린 | 5 | ||
3 | 계면활성제 | 폴리소르베이트20 | 2 |
(Tween 20) | |||
착향제 | 황금추출물 | 0.01 | |
녹차엑스(유기농) | 0.01 | ||
카모마일추출물(유기농) | 0.01 | ||
로즈마리엑스(유기농) | 0.01 | ||
민트향 HF-6585 | 0.2 | ||
합 계 | 100 |
성분 | 농도(mM) |
CaCl2 | 0.7 |
Mgcl2 | 0.2 |
K2HPO4 | 4 |
KCl | 30 |
NaN3 | 0.3 |
HEPES | 20 |
Claims (9)
- 하기 일반식 1의 아미노산 서열로 구성된 펩타이드를 포함하는 상아질 지각과민증 완화를 위한 구강 청결용 조성물:K-Y-R1-R2-R3-R4-R5-R6-R7-R8 (일반식 1)상기 일반식 1에서,R1은 아르기닌(R), 리신(K) 또는 글루타민(Q)이고;R2는 아르기닌(R) 또는 글루타민(Q)이며;R3, R4 및 R5는 각각 아르기닌(R) 또는 리신(K)이고;R6는 아스파라긴(N) 또는 세린(S)이며; 및R7 및 R8은 리신(K) 또는 타이로신(Y)이고,상기 조성물 100 중량부에 대하여 상기 펩타이드 0.00005-0.00015 중량부, 정제수 85-87 중량부, 계면활성제 1.7-2.9 중량부, 및 시트르산수화물 0.0045-0.0055 중량부를 포함하고,상기 조성물은 상아질 표면에 얇은 막을 형성함과 동시에 상아세관 안쪽 및 타액에 존재하는 인산-칼슘 이온과 결합하여 상아세관 및 상아질 표면에 재광화를 유도하는 것을 특징으로 하는 구강 청결용 조성물.
- 제1항에 있어서,상기 펩타이드는 서열번호 1 내지 96 중 어느 하나의 아미노산 서열로 구성된 것을 특징으로 하는 상아질 지각과민증 완화를 위한 구강 청결용 조성물.
- 제1항에 있어서,상기 조성물 100 중량부에 대하여 염화세틸피리디늄 0.0545-0.555 중량부가 포함되는 것을 특징으로 하는 상아질 지각과민증 완화를 위한 구강 청결용 조성물.
- 제1항에 있어서,상기 계면활성제는 폴록사머 또는 폴리소르베이트20인 것을 특징으로 하는 상아질 지각과민증 완화를 위한 구강 청결용 조성물.
- 제1항에 있어서,상기 계면활성제는 폴록사머407 12-14 중량%, 폴리소르베이트20 86-88 중량%를 포함하는 것을 특징으로 하는 상아질 지각과민증 완화를 위한 구강 청결용 조성물.
- 제1항에 있어서,상기 조성물 100중량부에 대하여 습윤제 9-11 중량부를 더 포함하는 것을 특징으로 하는 상아질 지각과민증 완화를 위한 구강 청결용 조성물.
- 제6항에 있어서,상기 습윤제는 D-소르비톨액 및/또는 농글리세린인 것을 특징으로 하는 상아질 지각과민증 완화를 위한 구강 청결용 조성물.
- 제7항에 있어서,상기 습윤제는 상기 D-소르비톨액 45-55 중량%, 상기 농글리세린 45-55 중량%를 포함하는 것을 특징으로 하는 상아질 지각과민증 완화를 위한 구강 청결용 조성물.
- 제1항에 따른 구강 청결용 조성물을 이를 필요로 하는 개체의 구강에 처리하는 단계를 포함하는 상아질 지각과민증 완화 방법.
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19800686.8A EP3791857A4 (en) | 2018-05-09 | 2019-04-17 | ORAL CARE COMPOSITION FOR THE RELIEF OF DENTIN HYPERESTHESIA |
MYPI2020005823A MY193395A (en) | 2018-05-09 | 2019-04-17 | Oral care composition for alleviating dentin hyperesthesia |
US17/053,410 US11612555B2 (en) | 2018-05-09 | 2019-04-17 | Oral care composition for alleviating dentine hyperesthesia |
SG11202011068TA SG11202011068TA (en) | 2018-05-09 | 2019-04-17 | Oral care composition for alleviating dentin hyperesthesia |
CA3099663A CA3099663C (en) | 2018-05-09 | 2019-04-17 | Oral care composition for alleviating dentin hyperesthesia |
BR112020022490-1A BR112020022490B1 (pt) | 2018-05-09 | 2019-04-17 | Composição para cuidado oral e método para aliviar hiperestesia dentinária |
CN201980031312.XA CN112105339B (zh) | 2018-05-09 | 2019-04-17 | 用于缓解牙本质感觉过敏的口腔清洁用组合物 |
AU2019265168A AU2019265168B2 (en) | 2018-05-09 | 2019-04-17 | Oral care composition for alleviation of dentine hyperesthesia |
MX2020011735A MX2020011735A (es) | 2018-05-09 | 2019-04-17 | Composicion de cuidado bucal para aliviar la hiperestesia dentinaria. |
RU2020140016A RU2763938C1 (ru) | 2018-05-09 | 2019-04-17 | Композиция для ухода за полостью рта для ослабления гиперестезии дентина |
JP2020560363A JP7185332B2 (ja) | 2018-05-09 | 2019-04-17 | 象牙質知覚過敏症緩和のための口腔衛生用組成物 |
JP2022144807A JP7469821B2 (ja) | 2018-05-09 | 2022-09-12 | 象牙質知覚過敏症緩和のための口腔衛生用組成物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2018-0053012 | 2018-05-09 | ||
KR1020180053012A KR101956578B1 (ko) | 2018-05-09 | 2018-05-09 | 상아질 지각과민증 완화를 위한 구강 청결용 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019216567A1 true WO2019216567A1 (ko) | 2019-11-14 |
Family
ID=65758559
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2019/004635 WO2019216567A1 (ko) | 2018-05-09 | 2019-04-17 | 상아질 지각과민증 완화를 위한 구강 청결용 조성물 |
Country Status (13)
Country | Link |
---|---|
US (1) | US11612555B2 (ko) |
EP (1) | EP3791857A4 (ko) |
JP (2) | JP7185332B2 (ko) |
KR (1) | KR101956578B1 (ko) |
CN (1) | CN112105339B (ko) |
AU (1) | AU2019265168B2 (ko) |
BR (1) | BR112020022490B1 (ko) |
CA (1) | CA3099663C (ko) |
MX (1) | MX2020011735A (ko) |
MY (1) | MY193395A (ko) |
RU (2) | RU2763938C1 (ko) |
SG (1) | SG11202011068TA (ko) |
WO (1) | WO2019216567A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2811919C1 (ru) * | 2020-06-09 | 2024-01-18 | Хайсенсбайо | Фармацевтическая композиция для предотвращения или лечения пародонтоза или травматического вывиха зуба |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101956578B1 (ko) | 2018-05-09 | 2019-03-11 | 주식회사 하이센스바이오 | 상아질 지각과민증 완화를 위한 구강 청결용 조성물 |
KR101956579B1 (ko) | 2018-05-09 | 2019-03-11 | 주식회사 하이센스바이오 | 상아질 지각과민증 완화를 위한 치약 조성물 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017072105A1 (en) * | 2015-10-26 | 2017-05-04 | Basf Se | Oral care products and methods comprising hydroxyapatite binding proteins |
KR101772449B1 (ko) * | 2016-12-27 | 2017-08-30 | 주식회사 하이센스바이오 | 신규한 펩타이드 |
KR101956578B1 (ko) * | 2018-05-09 | 2019-03-11 | 주식회사 하이센스바이오 | 상아질 지각과민증 완화를 위한 구강 청결용 조성물 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5624906A (en) * | 1994-12-08 | 1997-04-29 | Lever Brothers Company, Division Of Conopco, Inc. | Oral hygiene compositions comprising heteroatom containing alkyl aldonamide compounds |
JPH1017449A (ja) | 1996-07-05 | 1998-01-20 | Sangi Co Ltd | 知覚過敏症用組成物 |
JP2003160457A (ja) | 2001-11-27 | 2003-06-03 | Lion Corp | 象牙質知覚過敏予防・治療剤 |
CA2469498C (en) | 2002-01-03 | 2009-06-02 | The Procter & Gamble Company | Stable oral compositions comprising casein phosphopeptide complexes and fluoride |
JP2006518744A (ja) | 2003-02-21 | 2006-08-17 | ローディア インコーポレイティド | 抗感受性、抗カリエス、抗しみ、抗歯垢、ウルトラマイルド口腔衛生物質 |
CN1822810B (zh) | 2003-07-15 | 2010-09-29 | 花王株式会社 | 口腔用组合物 |
EP2249794A4 (en) | 2008-02-08 | 2014-01-08 | Colgate Palmolive Co | COMPOSITIONS AND METHODS COMPRISING BASIC AMINO ACID PEPTIDES AND PROTEASES |
KR101039802B1 (ko) | 2008-10-08 | 2011-06-09 | 주식회사 나이벡 | 치아 지각과민 방지용 조성물 |
EP2281543A1 (en) | 2009-07-27 | 2011-02-09 | The Procter & Gamble Company | Oral care compositions which comprise stannous and potassium salts |
RU2467739C1 (ru) * | 2011-10-31 | 2012-11-27 | Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" | Состав стоматологический для лечения гиперестезии зубов |
KR101401718B1 (ko) | 2012-08-08 | 2014-06-02 | 서울대학교산학협력단 | 히스톤 탈아세틸화효소 억제제를 포함하는 상아질 재생 촉진용 조성물 및 방법 |
AU2012387171B2 (en) | 2012-08-10 | 2015-05-07 | Colgate-Palmolive Company | Mouthwash comprising peroxy compound, a first acid and a second acid |
US10105303B2 (en) * | 2012-12-19 | 2018-10-23 | Colgate-Palmolive Company | Oral care composition comprising zinc amino acid halides |
MY180534A (en) | 2014-04-21 | 2020-12-01 | Lion Corp | Liquid composition for oral use and method for improving resilience to freezing thereof |
CA2960007C (en) | 2015-01-16 | 2019-01-08 | Kabushiki Kaisha Sangi | Toothpaste composition comprising a wax and a calcium phosphate |
US10952940B2 (en) * | 2016-01-15 | 2021-03-23 | University Of Washington | Reagents and methods for mineralization of tooth enamel |
KR101943978B1 (ko) | 2017-12-28 | 2019-01-30 | 주식회사 하이센스바이오 | 신규한 펩타이드 |
KR101956579B1 (ko) | 2018-05-09 | 2019-03-11 | 주식회사 하이센스바이오 | 상아질 지각과민증 완화를 위한 치약 조성물 |
-
2018
- 2018-05-09 KR KR1020180053012A patent/KR101956578B1/ko active IP Right Grant
-
2019
- 2019-04-17 CN CN201980031312.XA patent/CN112105339B/zh active Active
- 2019-04-17 MX MX2020011735A patent/MX2020011735A/es unknown
- 2019-04-17 SG SG11202011068TA patent/SG11202011068TA/en unknown
- 2019-04-17 RU RU2020140016A patent/RU2763938C1/ru active
- 2019-04-17 MY MYPI2020005823A patent/MY193395A/en unknown
- 2019-04-17 CA CA3099663A patent/CA3099663C/en active Active
- 2019-04-17 US US17/053,410 patent/US11612555B2/en active Active
- 2019-04-17 BR BR112020022490-1A patent/BR112020022490B1/pt active IP Right Grant
- 2019-04-17 JP JP2020560363A patent/JP7185332B2/ja active Active
- 2019-04-17 RU RU2021138615A patent/RU2021138615A/ru unknown
- 2019-04-17 EP EP19800686.8A patent/EP3791857A4/en active Pending
- 2019-04-17 AU AU2019265168A patent/AU2019265168B2/en active Active
- 2019-04-17 WO PCT/KR2019/004635 patent/WO2019216567A1/ko unknown
-
2022
- 2022-09-12 JP JP2022144807A patent/JP7469821B2/ja active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017072105A1 (en) * | 2015-10-26 | 2017-05-04 | Basf Se | Oral care products and methods comprising hydroxyapatite binding proteins |
KR101772449B1 (ko) * | 2016-12-27 | 2017-08-30 | 주식회사 하이센스바이오 | 신규한 펩타이드 |
KR101956578B1 (ko) * | 2018-05-09 | 2019-03-11 | 주식회사 하이센스바이오 | 상아질 지각과민증 완화를 위한 구강 청결용 조성물 |
Non-Patent Citations (5)
Title |
---|
ANONYMOUS: "BREATHAWAY MOUTH RINSE FRESH MINT- cetylpyridinium chloride mouthwash", DAILYMED, 23 February 2018 (2018-02-23), pages 1 - 5, XP055651567, Retrieved from the Internet <URL:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=37b2c031-ecc9-4420-9d84-e71c0e529187> * |
JUNG HS ET AL., J MOL HISTOL, 2011 |
PORTO, IC ET AL.: "Diagnosis and treatment of dentinal hypersensitivity", JOURNAL OF ORAL SCIENCE, vol. 51, no. 3, September 2009 (2009-09-01), pages 323 - 332, XP055651569 * |
TADURU SREENATH ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, no. 27, 4 July 2013 (2013-07-04), pages 24874 - 24880 |
WILLIAM T. BUTLER ET AL., CONNECTIVE TISSUE RESEARCH, vol. 44, 2003, pages 171 - 178 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2811919C1 (ru) * | 2020-06-09 | 2024-01-18 | Хайсенсбайо | Фармацевтическая композиция для предотвращения или лечения пародонтоза или травматического вывиха зуба |
Also Published As
Publication number | Publication date |
---|---|
JP2021521252A (ja) | 2021-08-26 |
RU2763938C1 (ru) | 2022-01-11 |
US11612555B2 (en) | 2023-03-28 |
SG11202011068TA (en) | 2020-12-30 |
AU2019265168B2 (en) | 2021-08-19 |
CA3099663C (en) | 2023-08-01 |
BR112020022490A2 (pt) | 2021-02-09 |
CN112105339B (zh) | 2024-04-30 |
JP7185332B2 (ja) | 2022-12-07 |
BR112020022490B1 (pt) | 2023-12-26 |
JP7469821B2 (ja) | 2024-04-17 |
CN112105339A (zh) | 2020-12-18 |
RU2021138615A (ru) | 2022-02-09 |
KR101956578B1 (ko) | 2019-03-11 |
US20210154123A1 (en) | 2021-05-27 |
EP3791857A4 (en) | 2022-05-11 |
EP3791857A1 (en) | 2021-03-17 |
AU2019265168A1 (en) | 2020-11-26 |
MX2020011735A (es) | 2021-01-08 |
JP2022177133A (ja) | 2022-11-30 |
CA3099663A1 (en) | 2019-11-14 |
MY193395A (en) | 2022-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019216568A1 (ko) | 상아질 지각과민증 완화를 위한 치약 조성물 | |
WO2019103203A1 (ko) | 신규 펩티드 및 이를 포함한 조성물 | |
WO2018124425A1 (ko) | 신규한 펩타이드 | |
WO2016190660A1 (ko) | 신규 펩티드 및 이를 포함한 조성물 | |
WO2015156649A1 (ko) | 섬유증 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물 | |
WO2019132352A1 (ko) | 신규한 펩타이드 | |
WO2016137162A1 (ko) | 청력 손상 방어용 펩타이드 및 이를 포함하는 조성물 | |
WO2016105086A1 (ko) | 안질환 치료 펩티드 및 이를 포함하는 안질환 치료용 조성물 | |
WO2019216567A1 (ko) | 상아질 지각과민증 완화를 위한 구강 청결용 조성물 | |
WO2018155997A1 (ko) | 에리스로포이에틴 유래 펩티드의 세포손상방지에 효과를 통한 활용 | |
WO2018088813A9 (ko) | Nkx3.2 단편 및 이를 유효성분으로 포함하는 약학 조성물 | |
WO2020004745A1 (ko) | 약물이 코팅된 마이크로 니들 및 이의 제조방법 | |
WO2018056706A1 (ko) | 티오레독신 결합단백질 유래 펩타이드 또는 이를 암호화 하는 폴리뉴클레오타이드를 유효성분으로 함유하는 노화 줄기세포의 역노화용 조성물 및 이의 용도 | |
WO2016167600A1 (ko) | 구강용 조성물 | |
WO2019132353A1 (ko) | Cpne4 단백질을 포함하는 상아질-치수질환 또는 치주질환 예방 또는 치료용 약학적 조성물 | |
WO2021251790A1 (ko) | 항비만 활성을 가지는 디옥시콜산-펩타이드 결합체 및 이의 용도 | |
WO2023054817A1 (ko) | 항노화 활성을 갖는 펩타이드 및 이의 용도 | |
WO2018021778A1 (ko) | Lrg1 당단백질을 포함하는 융합 단백질을 함유하는 발기부전, 허혈성 질환 또는 말초 신경질환의 예방 또는 치료용 조성물 | |
WO2024058315A1 (ko) | Cpne7 유래 펩타이드를 포함하는 상아질 접착용 조성물 및 치수복조용 조성물 | |
WO2021045520A1 (ko) | 섬유아세포 성장 인자 17을 포함하는 화장료 조성물 | |
WO2020138674A1 (ko) | 근육 이완용 조성물 | |
WO2023171900A1 (ko) | 치아우식증 예방 또는 치료용 조성물 | |
WO2019039630A1 (ko) | 폴리스타틴 유래 생리활성 펩타이드, 및 이의 용도 | |
WO2020222315A1 (ko) | 피부 또는 세포 투과능이 우수한 피부 주름 개선 또는 치료용 조성물 | |
WO2017111388A1 (ko) | 페리오스틴 유래 펩타이드를 유효성분으로 포함하는 혈관신생 촉진용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19800686 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2020560363 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3099663 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112020022490 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2019265168 Country of ref document: AU Date of ref document: 20190417 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019800686 Country of ref document: EP Effective date: 20201209 |
|
ENP | Entry into the national phase |
Ref document number: 112020022490 Country of ref document: BR Kind code of ref document: A2 Effective date: 20201104 |